Howard Levy
Insider
First SEC filing: Jan. 16, 2018 · Latest: Jan. 16, 2018
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net: $0
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Aug. 9, 2021 | GYRE | P | 639 | $3.62 | $2,313 | 639 Direct | · | Acquired | -86.9% (price as of 2026-10-02) |
| Feb. 9, 2021 | GYRE | P | 1,670 | $4.81 | $8,033 | 23,390 Indirect | +7.69% | Acquired | -90.1% (price as of 2026-10-02) |
| Feb. 8, 2021 | GYRE | A | 25,000 | · | · | 25,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Feb. 8, 2021 | GYRE | A | 25,000 | · | · | 25,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Aug. 10, 2020 | GYRE | P | 1,768 | $4.81 | $8,504 | 4,268 Direct | +70.72% | Acquired | -90.1% (price as of 2026-10-02) |
| March 16, 2020 | GYRE | P | 2,500 | $4.05 | $10,125 | 2,500 Direct | · | Acquired | -88.3% (price as of 2026-10-02) |
| Feb. 10, 2020 | GYRE | A | 1,358 | $6.23 | $8,460 | 1,358 Direct | · | Acquired | -92.4% (price as of 2026-10-02) |
| Jan. 23, 2020 | GYRE | A | 45,000 | · | · | 45,000 Direct | · | Acquired | (price as of 2026-10-02) |
| May 21, 2019 | GYRE | G | 16,094 | · | · | 16,094 Indirect | -50.00% | Disposed | (price as of 2026-10-02) |
| May 21, 2019 | GYRE | M | 4,400 | $4.63 | $20,372 | 16,094 Direct | +37.63% | Acquired | -89.8% (price as of 2026-10-02) |
| May 20, 2019 | GYRE | M | 4,400 | · | · | 81,218 Direct | -5.14% | Disposed | (price as of 2026-10-02) |
| Feb. 11, 2019 | GYRE | A | 2,485 | $7.04 | $17,494 | 11,867 Direct | +26.49% | Acquired | -93.3% (price as of 2026-10-02) |
| Jan. 31, 2019 | GYRE | M | 1,500 | · | · | 93,500 Direct | -1.58% | Disposed | (price as of 2026-10-02) |
| Jan. 31, 2019 | GYRE | M | 1,500 | $4.63 | $6,945 | 9,382 Direct | +19.03% | Acquired | -89.8% (price as of 2026-10-02) |
| Jan. 24, 2019 | GYRE | A | 35,000 | · | · | 35,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Nov. 26, 2018 | GYRE | M | 149 | · | · | 87,118 Direct | -0.17% | Disposed | (price as of 2026-10-02) |
| Nov. 26, 2018 | GYRE | M | 149 | $4.63 | $690 | 7,709 Direct | +1.97% | Acquired | -89.8% (price as of 2026-10-02) |
| Nov. 16, 2018 | GYRE | M | 173 | · | · | 87,267 Direct | -0.20% | Disposed | (price as of 2026-10-02) |
| Nov. 16, 2018 | GYRE | S 10b5-1 | 173 | $11.00 | $1,903 | 7,560 Direct | -2.24% | Disposed | -95.7% (price as of 2026-10-02) |
| Nov. 16, 2018 | GYRE | M | 173 | $4.63 | $801 | 7,733 Direct | +2.29% | Acquired | -89.8% (price as of 2026-10-02) |
| July 30, 2018 | GYRE | A | 35,000 | · | · | 35,000 Direct | · | Acquired | (price as of 2026-10-02) |
| May 3, 2018 | GYRE | M | 7,560 | · | · | 87,440 Direct | -7.96% | Disposed | (price as of 2026-10-02) |
| May 3, 2018 | GYRE | M | 7,560 | $4.63 | $35,003 | 7,560 Direct | · | Acquired | -89.8% (price as of 2026-10-02) |
| Jan. 12, 2018 | GYRE | A | 33,000 | · | · | 33,000 Direct | · | Acquired | (price as of 2026-10-02) |
| July 11, 2017 | GYRE | A | 95,000 | · | · | 95,000 Direct | · | Acquired | (price as of 2026-10-02) |
| April 18, 2016 | GYRE | A | 100,000 | · | · | 100,000 Direct | · | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Feb. 8, 2021 | GYRE | Stock Option (Right to Buy) | Common Stock | $5.89 | Feb. 8, 2031 | 25,000 | Acquired |
| Feb. 8, 2021 | GYRE | Stock Option (Right to Buy) | Common Stock | $5.89 | Feb. 8, 2031 | 25,000 | Acquired |
| Jan. 23, 2020 | GYRE | Stock Option (Right to Buy) | Common Stock | $6.85 | Jan. 23, 2030 | 45,000 | Acquired |
| May 20, 2019 | GYRE | Stock Option (Right to Buy) | Common Stock | $4.63 | July 11, 2027 | 4,400 | Disposed |
| Jan. 31, 2019 | GYRE | Stock Option (Right to Buy) | Common Stock | $4.63 | July 11, 2027 | 1,500 | Disposed |
| Jan. 24, 2019 | GYRE | Stock Option (Right to Buy) | Common Stock | $7.97 | Jan. 24, 2029 | 35,000 | Acquired |
| Nov. 26, 2018 | GYRE | Stock Option (Right to Buy) | Common Stock | $4.63 | July 11, 2027 | 149 | Disposed |
| Nov. 16, 2018 | GYRE | Stock Option (Right to Buy) | Common Stock | $4.63 | July 11, 2027 | 173 | Disposed |
| July 30, 2018 | GYRE | Stock Option (Right to Buy) | Common Stock | $9.68 | July 30, 2028 | 35,000 | Acquired |
| May 3, 2018 | GYRE | Stock Option (Right to Buy) | Common Stock | $4.63 | July 11, 2027 | 7,560 | Disposed |
| Jan. 12, 2018 | GYRE | Stock Option(Right to Buy) | Common Stock | $15.13 | Jan. 12, 2028 | 33,000 | Acquired |
| July 11, 2017 | GYRE | Stock Option (Right to Buy) | Common Stock | $4.63 | July 11, 2017 | 95,000 | Acquired |
| April 18, 2016 | GYRE | Stock Option (Right to Buy) [F1] | Common Stock | $1.52 | April 18, 2026 | 100,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2020 | $450,348 | · | · | · | $112,342 | · | $14,349 | $826,709 |
| 2019 | $419,500 | · | · | · | $110,000 | · | $4,239 | $733,018 |
| 2018 | $397,838 | $139,230 | · | · | · | · | $3,317 | $1,198,847 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.